Synapse - Eytan Stein

Results (371)

Safety and efficacy of AG-221, a potent inhibitor of mutant IDH2 that promotes differentiation of myeloid cells in patients with advanced hematologic malignancies: Results of a phase 1/2 trial

Meeting Abstract

Stein, E. M.; DiNardo, C.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Kantarjian, H. M.; Sekeres, M. A.; Fathi, A. T.; Flinn, I. W.; Frankel, A. E.; more...
Blood (2015)

Fulltext@MSK | Save

SGN-CD33A plus hypomethylating agents: A novel, well-tolerated regimen with high remission rate in frontline unfit AML

Meeting Abstract

Fathi, A. T.; Erba, H. P.; Lancet, J. E.; Stein, E. M.; Walter, R. B.; DeAngelo, D. J.; Faderl, S.; Jillella, A. P.; Ravandi, F.; Advani, A. S.; more...
Blood (2015)

Fulltext@MSK | Save

Molecular profiling and relationship with clinical response in patients with IDH1 mutation-positive hematologic malignancies receiving AG-120, a first-in-class potent inhibitor of mutant IDH1, in addition to data from the completed dose escalation portion of the phase 1 study

Meeting Abstract

DiNardo, C.; de Botton, S.; Pollyea, D. A.; Stein, E. M.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I. W.; Altman, J. K.; more...
Blood (2015)

Fulltext@MSK | Save

IDH2 inhibition in AML: Finally progress?

Journal Article

Stein, E. M.
Best Practice and Research: Clinical Haematology (2015)

Fulltext@MSK | Save

DH2 inhibitors in acute myeloid leukemia

Meeting Abstract

Coombs, C. C.; Stein, E. M.; Levine, R. L.; Tallman, M. S.
Annals of Hematology (2015)

Fulltext@MSK | Save

Ag-221, an oral, selective, first-in-class, potent inhibitor of the IDH2 mutant enzyme, induced durable responses in a phase 1 study of IDH2 mutation-positive advanced hematologic malignancies

Meeting Abstract

DiNardo, C.; Stein, E. M.; Altman, J. K.; Collins, R.; DeAngelo, D. J.; Fathi, A. T.; Flinn, I.; Frankel, A.; Levine, R. L.; Medeiros, B. C.; more...
Haematologica (2015)

Fulltext@MSK | Save

Clinical safety and activity of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a phase 1 study of patients with advanced IDH1-mutant hematologic malignancies

Meeting Abstract

de Botton, S.; Pollyea, D. A.; Stein, E. M.; DiNardo, C.; Fathi, A. T.; Roboz, G. J.; Collins, R.; Swords, R. T.; Flinn, I.; Altman, J. K.; more...
Haematologica (2015)

Fulltext@MSK | Save

Targeting PML-RARα with retinoids

Book Section

Stein, E. M.; Tallman, M. S.
In Andreeff, M. (Eds.) Targeted Therapy of Acute Myeloid Leukemia (2015)

Fulltext@MSK | Save

Melanoma and non-melanoma skin cancers in hairy cell leukaemia: A Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center